Gynecological malignancies such as cancer of the cervix, ovary, endometrium, vulva, and vagina pose a severe global health burden. Although conventionally attributed to genetic mutation, hormonal imbalance, and chronic viral infection, including high-risk human papillomavirus, recent evidence suggests that the human microbiome plays a central role in their pathogenesis and development.
This review summarizes existing evidence that microbial dysbiosis, specifically the depletion of beneficial Lactobacillus species and overrepresentation of anaerobic organisms such as Fusobacterium, Atopobium, and Sneathia, is implicated in carcinogenesis pathways. These include chronic inflammation, immune modulation, loss of epithelial barrier integrity, microbial metabolite toxicity, and estrogen metabolism by the estrobolome.
Dysbiosis in the gut and reproductive tract has been associated with HPV persistence, tumor microenvironment remodeling, and immune surveillance/therapy resistance. Consequently, microbial signatures are being investigated as a potentially successful non-invasive biomarker for early diagnosis, prognosis, and monitoring of therapy in gynecological oncology.
In addition, emergent microbiome-based therapies are being considered as potential adjunct therapies, including probiotics, prebiotics, dietary manipulation, vaginal microbiota transplantation, and fecal microbiota transplantation.
This review synthesizes current literature linking the human microbiome to cancers of the female reproductive tract (cervix, ovary, endometrium, vulva, vagina).
It frames microbial community shifts as potential contributors to pathogenesis and as sources of diagnostic and therapeutic innovation.
The article is a narrative review summarizing observational and mechanistic studies.
Specific study designs, sample sizes, and statistical measures were not reported in the source abstract supplied.
The review emphasizes that loss of Lactobacillus dominance and enrichment of anaerobes (examples cited include Fusobacterium, Atopobium, Sneathia) characterize dysbiosis associated with gynecological malignancy.
Gut and reproductive-tract microbiome alterations are discussed in relation to persistent viral infection and local ecosystem disruption.
Authors attribute putative oncogenic effects to pathways explicitly described in the source: chronic inflammation, modulation of host immunity, compromised epithelial barrier function, toxic microbial metabolites, and estrogen metabolism mediated by the estrobolome.
The review notes active investigation of microbial signatures as noninvasive biomarkers for early detection, prognostication, and therapy monitoring.
It also outlines candidate adjunctive interventions being explored, including probiotics, prebiotics, dietary change, vaginal microbiota transfer, and fecal microbiota transplantation.
The source indicates translational gaps and limitations but does not enumerate specific methodological constraints or evidence strength metrics in the provided excerpt.